Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients

Journal of the American College of Cardiology

Volumn 55, Issue 12, 2010, Pages 1209-1216

  Koh, Kwang Kon ^a   Quon, Michael J ^b   Han, Seung Hwan ^a   Lee, Yonghee ^c   Kim, Soo Jin ^a   Shin, Eak Kyun ^a  

^a Gachon University College of Medicine   (South Korea)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c University of Seoul   (South Korea)

Author keywords

adipocytokines; glycated hemoglobin; insulin resistance; metabolic syndrome; statins

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; GLYCOSYLATED HEMOGLOBIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT DURATION;

ADULT; AGED; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 77949300393     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.053     Document Type: Article

References (23)

1. Kim J., Montagnani M., Koh K.K., and Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113 (2006) 1888-1904
2. Muniyappa R., Montagnani M., Koh K.K., and Quon M.J. Cardiovascular actions of insulin. Endocr Rev 28 (2007) 463-491
3. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47 (2000) 648-657
4. Yada T., Nakata M., Shiraishi T., and Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 126 (1999) 1205-1213
5. Kanda M., Satoh K., and Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 26 (2003) 1681-1684
6. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., and Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia 49 (2006) 1881192
7. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
8. Sever P.S., Dahlof B., Poulter N.R., et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
9. Ridker P.M., Danielson E., Fonseca F.A., et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
10. Coleman C.I., Reinhart K., Kluger J., and White C.M. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 24 (2008) 1359-1362
11. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
12. Koh K.K., Quon M.J., Han S.H., et al. Simvastatin improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 31 (2008) 776-782
13. Koh K.K., Quon M.J., Han S.H., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204 (2009) 483-490
14. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of patients with combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
15. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
16. Takagi T., Matsuda M., Abe M., et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 196 (2008) 114-121
17. Muniyappa R., Lee S., Chen H., and Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294 (2008) E15-E26
18. Jick S.S., and Bradbury B.D. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 58 (2004) 303-309
19. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357-362
20. Keech A., Colquhoun D., Best J., et al., LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26 (2003) 2713-2721
21. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53 (2009) 298-304
22. Reaven P.D., Moritz T.E., Schwenke D.C., et al., Veterans Affairs Diabetes Trial. Intensive glucose lowering therapy reduces cardiovascular disease events in VADT participants with lower calcified coronary atherosclerosis. Diabetes 58 (2009) 2642-2648
23. Koh K.K., Son J.W., Ahn J.Y., et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22 (2002) e19-e23